Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Diabetes Obes Metab. 2022 May;24(5):838-848. doi: 10.1111/dom.14642. Epub 2022 Feb 8.
Diabetes Obes Metab. 2022.
PMID: 34984815
Free PMC article.
Clinical Trial.